Pixacare secures 3 million euros in funding for its remote wound healing monitoring software

Pixacare, a start-up based in Strasbourg (Grand Est) and specialized in remote monitoring of wound healing, announced on April 25 a fundraising of 3 million euros. The funding round was led by French venture capitalist Elaia, with the support of Bpifrance's French Tech Seed fund, 50partners and business angels. In November 2021, Pixacare had already raised 1.9 million euros.

Determine the contour and content of wounds remotely

The start-up was founded in 2019 by Matis Ringdal and Vincent Marceddu, with the support of Professor Frédéric Bodin, plastic surgeon at Strasbourg University Hospital. She has developed a secure application, allowing wounds to be photographed. Using artificial intelligence algorithms, the contour and content of the wounds are analyzed. Percentages of necrosis, fibrin and budding make it possible to visualize the progress of healing. In France, around 2.5 million people suffer from chronic wounds.

The application developed by Pixacare is aimed at general practitioners, surgeons, and nurses. The start-up has already signed partnerships with around thirty establishments, including the University Hospitals of Brest, Lille, Nantes and Strasbourg, and the Gustave-Roussy and Curie institutes. The University Hospital of Liège (Belgium) has also deployed the application.

The start-up claims 70,000 patients monitored

With its solution, Pixacare claims to support and monitor 70,000 patients, with 400,000 photos. According to a study currently being published, this remote monitoring would reduce healing time by 33%, reduce follow-up consultations by 55% and reduce the cost per patient by 1,500 euros over six months. A first study published in June 2021 demonstrated a time saving for the medical profession of 3 minutes 10 minutes per patient, or 1 hour 30 minutes per day on average.

Pixacare is counting on this fundraising to reach out to more doctors in France, and to legally validate its wound analysis algorithms. Since its last round of financing, it has affixed the CE marking to its product. Finally, it intends to finance clinical studies to ultimately obtain reimbursement from Health Insurance.